Value proposition

CardioSignal is developing a disruptive mobile application-based technology to improve the detection of heart disease.

CardioSignal is a health technology company developing groundbreaking solutions for early detection of heart diseases. We are based in Turku, Finland and Palo Alto, CA, United States. The CardioSignal mobile application is a CE-marked class IIa medical device for the detection of atrial fibrillation, available in over 10 countries. The technology we are developing enables a digital cardiac biomarker for other major heart diseases as well.

CardioSignal is a brand and a product by Precordior. Originally an academic spinoff, the company’s patented motion sensor technology is built on a decade of research and algorithm development.

Our purpose
We are supporting healthcare in battling the #1 killer of people in the world. With heart disease numbers only rising, we are facing a health and economic problem described as an epidemic by researchers and physicians around the world.

Early identification and treatment of heart disease, such as atrial fibrillation, would help prevent strokes and heart attacks and improve outcomes for individuals and society.